David Ferry

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.4K citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +7

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Charles S. Fuchs, Jiří Tomášek, Filip Dumitru et al. · The Lancet · 2013 · 2.2K citations · Full text

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +11

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Eric Van Cutsem, Josep Tabernero, Radek Lakomý et al. · Journal of Clinical Oncology · 2012 · 1.4K citations

Outcomes in Patients with Acute Non–Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy

William E. Boden, Robert A. O’Rourke, Michael H. Crawford et al. · New England Journal of Medicine · 1998 · 805 citations · Full text

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González et al. · The Lancet Oncology · 2013 · 723 citations · Full text

Oncology, Open-label Phase 3, Cancer Management +7